Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.

CONCLUSION: Brigatinib was granted accelerated approval for the treatment of patients with metastatic ALK+ NSCLC who have progressed on or are intolerant to crizotinib. In a subset of NSCLC patients, brigatinib increases survival for approximately 1 year; however, side effects were detected.
PMID: 30638036 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - January 13, 2019 Category: Drugs & Pharmacology Authors: Spencer SA, Riley AC, Matthew A, Di Pasqua AJ Tags: Ann Pharmacother Source Type: research